In one study, the maytansinoid tubulin inhibitor, DM4, was targeted to mesothelioma, pancreatic, and ovarian tumors overexpressing mesothelin by conjugation to an anti-mesothelin antibody via a disulfide-containing linker [111]. Here, MSLN is linked to ovarian neoplasm.